🇺🇸 FDA
Pipeline program

ALN-RSV01

ALN-RSV01-105

Phase 2 small_molecule completed

Quick answer

ALN-RSV01 for Respiratory Syncytial Virus Infections is a Phase 2 program (small_molecule) at ALNYLAM PHARMACEUTICALS, INC. with 3 ClinicalTrials.gov record(s).

Program details

Company
ALNYLAM PHARMACEUTICALS, INC.
Indication
Respiratory Syncytial Virus Infections
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials